Alternatives to Trulicity (Dulaglutide) for Patients with Cardiovascular Disease or High Cardiovascular Risk

GLP-1 Receptor Agonist Alternatives (Same Drug Class)

The European Society of Cardiology recommends semaglutide or liraglutide as the preferred first-line alternatives to Trulicity for patients with cardiovascular disease, due to their proven cardiovascular benefits 1, 2, 3
Semaglutide provides very high glucose-lowering efficacy, superior weight loss compared to dulaglutide, and proven MACE reduction in patients with type 2 diabetes and cardiovascular disease, with no dose adjustment required for renal impairment 3, 4, 5, 6
Liraglutide offers high glucose-lowering efficacy, proven reduction in MACE and cardiovascular death, and particularly strong benefits in patients with eGFR <60 mL/min/1.73 m², with no dose adjustment required for renal impairment 1, 5, 6, 8

The American Diabetes Association recommends empagliflozin, canagliflozin, or dapagliflozin for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, due to their ability to reduce MACE, heart failure hospitalization, cardiovascular death, and CKD progression 1, 2, 9
SGLT2 inhibitors maintain cardiovascular and kidney benefits even in patients with renal impairment, although glucose-lowering efficacy diminishes below eGFR 45 mL/min/1.73 m² 3, 4, 6

Tirzepatide provides very high glucose-lowering efficacy and very high weight loss, superior to dulaglutide, although its cardiovascular and heart failure outcomes are still under investigation 3, 4

For patients with cardiovascular disease or high cardiovascular risk, prioritize semaglutide or liraglutide for MACE reduction, according to the European Society of Cardiology 1, 2, 8
For patients with heart failure or CKD, prioritize SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) for their cardiovascular and kidney benefits, as recommended by the American Heart Association 1, 2, 9